ArticleMolecular therapy oncolytics2020
Lactate Dehydrogenase A Depletion Alters MyC-CaP Tumor Metabolism, Microenvironment, and CAR T Cell Therapy.
Open access · goldAbstract read
In one paragraph
Article in Molecular therapy oncolytics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Malic enzyme 1 senses L-lactate to determine tumor heterogeneity.Signal transduction and targeted therapy · 2026Article
- Lactylation Remodels Tumorigenesis, Immune Microenvironment, and Therapeutic Response.Current issues in molecular biology · 2026Review
- CLL-1: An emerging target for immunotherapy in acute myeloid leukemia.Annals of hematology · 2026Review
- Nanomedicine Meets Immunotherapy: Transforming Chimeric Antigen Receptor T Cell Treatment for Solid Tumors.Small science · 2026Review
- The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells.Frontiers in immunology · 2026Review
- Beyond small molecules: advancing MYC-targeted cancer therapies through protein engineering.Transcription · 2025Review
- Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors.Current issues in molecular biology · 2025Review
- Revolutionizing Cancer Treatment: Unveiling the Power of CAR T-cell Therapy.Current pharmaceutical design · 2025Review
- Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy.Frontiers in immunology · 2025Review
- Review
- MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.Aging and disease · 2024Review
- The Role of Tumor Metabolic Reprogramming in Tumor Immunity.International journal of molecular sciences · 2023Review
- RNA Therapeutics for Improving CAR T-cell Safety and Efficacy.Cancer research · 2023Review
- Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy.Frontiers in immunology · 2023Review
- The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies.Frontiers in immunology · 2023Review
- Metabolism in the progression and metastasis of brain tumors.Cancer letters · 2022Review
- Article
- LDH-A-Modulation and the Variability of LDH Isoenzyme Profiles in Murine Gliomas: A Link with Metabolic and Growth Responses.Cancers · 2022Article
- Microenvironmental influences on T cell immunity in cancer and inflammation.Cellular & molecular immunology · 2022Review
- LDHA: The Obstacle to T cell responses against tumor.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 2 institutions in 2 countries.
Mayuresh M ManeDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ivan J CohenGerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ellen AckerstaffDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Khalid ShalabyDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jenny N IjomaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Myat KoDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Masatomo MaedaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Avi S AlbegDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kiranmayi VemuriDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jaya SatagopanDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Anna MorozMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Juan ZuritaMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Larissa ShenkerMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Masahiro ShindoDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Tanner NicklesGerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ekaterina NikolovDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Maxim A MorozMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jason A KoutcherDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Inna SerganovaDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Vladimir PonomarevMolecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Ronald G BlasbergDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MImaging tumor and T cell responses to metabolic and immune modulation therapyR01CA215136 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI KOUTCHER, JASON ARTHUR, MERGHOUB, TAHA · 2017 to 2021
$3.8MImaging Immune Modulation in Chimeric Antigen Receptor (CAR) T Cell TherapyR01CA204924 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2016 to 2020
$3.5MImage-guided TRAIL-enhanced CAR T-cell immunotherapyR01CA220524 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI PONOMAREV, VLADIMIR · 2018 to 2022
$2.9MTumor microenvironment: Impact on T cell tumor-targeting, activation and survivalR01CA163980 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BLASBERG, RONALD GEORGE, PONOMAREV, VLADIMIR · 2012 to 2016
$2.5MExploiting tumor metabolism to optimize T cell therapyR50CA221810 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Inna Serganova · 2018 to 2026
$1.6MImaging the efficacy of TRAIL-enhanced cancer immunotherapyR21CA213139 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S., PONOMAREV, VLADIMIR · 2017 to 2018
$413kNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA163980NCI NIH HHS R01 CA204924NCI NIH HHS R01 CA215136NCI NIH HHS R01 CA220524NCI NIH HHS R21 CA213139NCI NIH HHS R50 CA221810
Abstract
To enhance human prostate-specific membrane antigen (hPSMA)-specific chimeric antigen receptor (CAR) T cell therapy in a hPSMA
Indexed as
bioluminescence imagingBLICARchimeric antigen receptorhPSMAhuman prostate-specific membrane antigenlactatelactate dehydrogenase ALDH-Aluciferase reportersmagnetic resonance spectroscopyMRSprostate cancerT cellsTMEtumor metabolismtumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.